Breaking News, Collaborations & Alliances

HanAll Biopharma, Daewoong Pharma Invest in Vincere Biosciences

Fosters collaborative opportunities in Parkinson's Disease therapeutics as well as Vincere's artificial intelligence platform.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

HanAll Biopharma and Daewoong Pharmaceutical have expanded their open collaboration strategy by investing in Vincere Biosciences, a Cambridge, MA-based company developing therapeutics targeting mitophagy. These investments, via the Freemind Investments (FMI) investment platform, fosters collaborations around Parkinson’s disease therapeutics as well as Vincere’s artificial intelligence platform, which ranges from tools to accelerate drug discovery to algorithms that assist with subjec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters